The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Astellas Pharma Inc. (ALPMY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Astellas Pharma Inc. is one of 1000 companies in the Medical group. T ...

Core Insights - Singlera Genomics has developed a refined approach to detect drug-induced testicular toxicity using its cell-free DNA methylation technology in collaboration with Astellas [1][2] - The mTitan technology has previously been effective in non-invasively detecting methylation signals from various cancers, potentially up to four years before clinical evidence appears [2] - The collaboration aims to expedite drug development pipelines by allowing faster screening for drug-induced cytotoxicity [3] Company Overview - Singlera Genomics Inc. specializes in non-invasive genetic diagnosis and was established in July 2014, with a global presence and R&D centers [4] - The company is recognized for its proprietary technologies in single-cell sequencing, DNA methylation, and bioinformatics, contributing significantly to the genomics field [4]

Core Viewpoint - Astellas Pharma has received FDA approval for expanded prescribing information for IZERVAY, allowing for indefinite dosing duration in the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), enhancing treatment flexibility for physicians and patients [1][2]. Group 1: Product Approval and Clinical Data - The FDA's approval followed Astellas' resubmission of the supplemental New Drug Application on December 26, 2024, after addressing feedback from a Complete Response Letter issued in November 2024 [2]. - The updated label for IZERVAY is based on positive results from the GATHER2 Phase 3 clinical trial, which demonstrated a statistically significant slowing of GA progression over two years [3][5]. - The GATHER2 study showed that IZERVAY reduced the rate of GA lesion growth compared to sham treatment, with benefits observed as early as six months and increasing over time [5][6]. Group 2: Market Performance and Safety Profile - Since receiving a permanent J-code in April 2024, IZERVAY has experienced month-over-month growth, with over 210,000 vials distributed by the end of December 2024 [4]. - Post-marketing safety reports have shown consistent results with clinical trial data, with no new significant safety signals identified, reinforcing confidence in IZERVAY's safety profile [4][6]. - The incidence of choroidal neovascularization was slightly higher in the IZERVAY group (11.6%) compared to sham (9%) over two years [6]. Group 3: Financial Impact - The financial impact of the approval on Astellas' results for the fiscal year ending March 31, 2025, is expected to be minor [7]. Group 4: Company Overview - Astellas is a global life sciences company focused on innovative therapies in various disease areas, including ophthalmology, and is committed to addressing high unmet medical needs through research and development [19].

TOKYO, Feb. 4, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective April 1, 2025.Regarding the Changes in Management StructureAstellas aims to create and deliver "VALUE" for patients. To promote drug discovery activities swiftly and efficiently from the early stages of research through to commercialization with patient-centric approach, Astellas will change its management structur ...

"Cooler Moments" educates and empowers women in midlife to speak up for themselves and celebrate this natural change in their lives.NORTHBROOK, Ill., Dec. 5, 2024 /PRNewswire/ -- Astellas Pharma US, Inc. (TSE: 4503, Head of US Commercial: Michael Petroutsas, "Astellas") today announced the launch of Cooler Moments in partnership with Dr. Jen Ashton, a leading women's health medical expert, Founder and President of Ajenda, and former network news Chief Medical Correspondent who is board-certified in OBGYN an ...

SAN FRANCISCO, Nov. 20, 2024 /PRNewswire/ -- Astellas Pharma U.S., Inc. (President: Mike Petroutsas, "Astellas") today announced that it has entered into an agreement with Desert Oasis Healthcare (DOHC), a member of Heritage Provider Network, to pilot DIGITIVA™, a non-invasive digital health solution for the management of heart failure patients. In the next few weeks, eligible patients receiving care with DOHC will begin using DIGITIVA as a new method for managing their heart health while working in partner ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe ...

Financial Data and Key Metrics - Revenue increased by 22% year-on-year to 935.6 billion yen, with core operating profit rising by 36.2% to 183.1 billion yen [7][9] - Operating profit increased by 69.9% year-on-year to 93.7 billion yen, while net profit surged by 105.3% to 73.5 billion yen [9] - Full-year revenue and core operating profit forecasts were revised upward, shifting from an initial profit decline forecast to a profit increase forecast [8] Business Line Performance - XTANDI global sales grew by 25% year-on-year to 451.7 billion yen, driven by strong performance in the US and ex-US regions [10] - Strategic Brands (PADCEV, IZERVAY, VEOZAH, VYLOY, XOSPATA) collectively exceeded 150 billion yen in sales, with a year-on-year growth of over 90 billion yen [11] - PADCEV sales surged by 131% year-on-year to 75.4 billion yen, while IZERVAY sales reached 28.1 billion yen, exceeding initial expectations [11][12] - VEOZAH sales grew steadily to 14.8 billion yen, with 18 countries launched, contributing to regional expansion [12] - VYLOY, launched in Japan in June, achieved 1.2 billion yen in sales within four months, with approvals in Europe and the US expected to drive further growth [12][13] - XOSPATA global sales increased by 32% year-on-year to 34.8 billion yen, driven by increased FLT3 testing in the US [13] Market Performance - In the US, XTANDI benefited from market growth and the penetration of the M0 CSPC indication, with ex-US regions also performing well [10] - PADCEV saw rapid market penetration in the US, with a 55% new patient share, and growth in Europe and Japan following new approvals [15][16] - IZERVAY achieved a 40% market share in the US, with over 143,000 vials shipped since launch, and a new DTC campaign launched to raise disease awareness [18][19] Strategic Direction and Industry Competition - The company revised its full-year revenue forecast upward by 150 billion yen to 1.8 trillion yen, driven by strong performance from XTANDI and Strategic Brands [22] - The company is focusing on lifecycle management (LCM) initiatives for Strategic Brands, with new indications expected for PADCEV, VYLOY, and XOSPATA in the coming years [33] - The Focus Area Approach aims to advance flagship programs in immuno-oncology, targeted protein degradation, genetic regulation, and blindness/regeneration, with POC judgments expected by FY2025 [34][35] - The company is pursuing cost optimization initiatives to achieve a target operating margin of 30%, with expected savings of 120-150 billion yen by FY2027 [36][37] Management Commentary on Operating Environment and Future Outlook - Management highlighted the strong performance of XTANDI and Strategic Brands, with robust demand trends globally [10][11] - The company expects to offset the negative impact of the US IRA Medicare Part D redesign through strong global sales growth [10] - Management expressed confidence in the clinical profile of IZERVAY and is exploring options to bring the product to patients outside the US, including in Europe [25][26] - The company is committed to sustainable growth through cost optimization, lifecycle management, and pipeline development [38][39] Other Important Information - The company booked a net foreign exchange loss of 12.2 billion yen due to currency fluctuations [9] - SG&A expenses increased by 10.2% year-on-year, but the SG&A ratio to revenue improved by 3.2 percentage points due to cost management and Strategic Brands expansion [20] - R&D expenses increased by 21.4% year-on-year, driven by investments in clinical trials and in-house capabilities [20][21] Q&A Session Summary Question: Impact of IZERVAY label update and DTC campaign in the US - The label update impact was included in the initial plan, and the DTC campaign is expected to drive market expansion from Q3 onwards [43][44] Question: IZERVAY filing process in Europe and other regions - The company is exploring individual country submissions in Europe and consulting with regulatory authorities in Japan, China, and other regions [45][46][47] Question: Potential impairment loss on IZERVAY - The company is evaluating the asset value of IZERVAY outside the US, considering factors such as sales performance and competitive environment, but no specific impairment loss has been determined yet [53][54][55] Question: XTANDI growth outlook considering IRA impact - Management expects continued growth for XTANDI, driven by market expansion and patient retention, but the net impact of IRA and other factors will be clearer in FY2025 [56][57][58] Question: Capital allocation and shareholder returns - The company plans to prioritize business growth investments, with stable dividend increases and potential share buybacks if excess cash is available [60][61] Question: Competitive landscape for XTANDI - XTANDI's unique position in early-stage disease treatment and strong EMBARK data differentiate it from competitors, with Johnson & Johnson and Bayer being the main competitors in this space [66] Question: Future business development and pipeline strategy - The company will focus on advancing its primary focus flagship programs and may consider business development opportunities depending on pipeline progress and market conditions [67][68] Question: IZERVAY's competitive advantages in the US market - IZERVAY's strong safety profile and physician assessment have contributed to its market share growth, with 60% of new patients being placed on IZERVAY [70][71][72] Question: AVB-101 licensing and gene therapy strategy - The company is targeting monogenic diseases with high unmet medical needs, using AVB-101 as a potential platform for future gene therapy expansion [73][74][75] Question: IZERVAY's DTC campaign and market expansion - The DTC campaign aims to raise disease awareness and drive patient referrals, with the company also targeting generalist ophthalmologists to increase diagnosis and treatment rates [79][80][81] Question: Sustainable margin transformation initiatives - The company is enhancing in-house capabilities for clinical development, reducing outsourcing costs, and improving operational efficiency to achieve cost optimization targets [83][84][86] Question: Internal penetration of cost optimization initiatives - The company's cost optimization initiatives are being implemented enterprise-wide, with strong top-down and bottom-up support [89][90] Question: Enhancing in-house capabilities for clinical development - The company is reducing reliance on CROs and building internal capabilities to conduct global clinical studies more efficiently and cost-effectively [92][93]

Astellas Pharma Inc. ( OTCPK:ALPMF ) is a Japanese pharmaceutical company focusing most of its efforts in the oncology space. They do not get much visibility despite their status among the mid-size pharma contenders in the oncology I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their curren ...